

# Faculty Disclosures

2025 PVA Summit + Expo  
Activity Dates: August 24 - 27, 2025

## **Naghmeh Abbasi Kasbi, M.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

## **Tim Abeska, J.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

## **Jonathon Acierno, BSN, RN, PCCN, CMSRN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

## **Margaret Arnold, PT**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

## **Amani Assiry, MsRT**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

## **Ernest John Aucone, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

## **Francesca Bagnato, MD. Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

## **Anne Lord Bailey, PharmD, BCPS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mandi Bailey, BS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Kelsey Berryman, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Kath Bogie, D.Phil, FAIMBE**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Joyce Boyd, DNP, AGNP**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Jill Brattain, B.Sc.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Christine Brown, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Shane Chanpimol, PT, DPT, NCS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Julia Ines Coschignano, B.Sc.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Nora Curtin, B.S**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Evan Davis, CTRS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Blair Dellenbach, MSOT, OTR/L**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Elizabeth Dominick, PT, DPT, NCS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Philip Effraim, MD, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Emily Brooks Ehlers, PT, DPT, CLT, ATP**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Miss Bethany Ferguson, LCSW-C, CCM**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Kathryn Fitzgerald, PT, DPT, NCS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mr. Martin B Forchheimer, MPP**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Nora Fritz, PT, DPT, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Allison Fryman, MPH**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Julio C Furlan, MD, LLB, MBA, MSc, PhD, FRCPC, FAAN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mrs Abrity Gomes, HBSc**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Ashraf S. Gorgey, MPT, PhD, FACSM, FACRM**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Glenn D. Graham, MD, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Jaimie Grane, MSN, RN, CRRN, NPD-BC**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Letitia Graves, PhD, RN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mr. Andrew Grossman, MMS, PA-C**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Robert Charles Hand, PT, DPT, NCS, ATP**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Andrew Hansen, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Juli Harrison, OTD, OTR/L, ATP**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Geoffrey Henderson, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr M. Kristi Henzel, MD, Ph.D**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Rachel M. Hibbs, DPT, NCS, ATP/SMS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. Pauline (Tony) Hilton, DrPH, RN, MSN, FNP, CRRN, FARN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Cassandra Hogan, PT, DPT, NCS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Ileana Howard, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Shelly Hsieh, M.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Christina Hughes, MD, FCTMSS**

No relevant financial relationships associated with the content of this activity to disclose.

Unapproved drug or product uses: This presentation will clearly delineate between current FDA treatment protocols and those that have not yet gone through the FDA approval process but have clear, abundant, level A research to support their clinical safety and efficacy. The VA currently supports treatment protocols for neuropathic pain in their clinical guidelines that are not yet FDA approved. No protocols are treatments will be discussed that have been DENIED by the the FDA.

**Dr. Dora Ifon, PhD, AGPCNP-BC**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Tessa C. Johnson, M.S.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Swapna Johnson-Kunjukutty, M.D. IIWCC-NYU**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. April Jalmillah Jones, R.N., BSN, CRRN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Diane Kaliris, PT, DPT, NCS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Jaewon Kang, Ph.D., MSOT**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Sierra Dawn Kauer, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

Unapproved drug or product uses: Romidepsin is an approved chemotherapy drug that we are exploring for the purposes of relieving spasticity after SCI. Andrew Tan holds a provisional patent filed through the VA Technology Transfer Service (VA TTS) to develop Romidepsin in a new indication for neuropathic pain (U.S. Application No. 63/222,305)

**Dr. Melinda S Kavanaugh, Ph.D., LCSW**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Sarah Kiefer Luhring, M.A., CCC-SLP, ATP, CBIS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Martin Kilbane, PT, DPT, OCS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Alicia M Koontz, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. Cherry Lazam Kunkel, MSN, RN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Sherri L. LaVela, Ph.D., MPH, MBA**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mrs. Darling, Leah, LCSW**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ashley Lee, MS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Jeannine Leonard, MSN, RN, NE-BC**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Michael Lewin, MD**

- Biogen: Speaker/Consultant/Advisory Board
- Novartis: Speaker/Consultant/Advisory Board
- Roche: Speaker/Consultant/Advisory Board

No discussion of unapproved drug or product uses.

**Ziwei Li, M.S.O.T**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.



**Mark H Lichter, AIA**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Christine Marie Macri, MSN, RN, CMSRN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Heidi Wynn Maloni, Ph.D., RN, ANP-BC, CNRN, MSCN, FAAN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Mark Manago, PT, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Kyrstina Hudson Mariouw**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mr. Daniel S. McPartlin, PA**

No relevant financial relationships associated with the content of this activity to disclose.

Unapproved drug or product uses: Use of amoxicillin 250 mg one-time dose for the purposes of oral amoxicillin challenge to remove erroneous pencicillin allergies from the medical record as per protocol approved by local Pharmacy & Therapeutics Committee.

**Dr. Paul Mehta, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**MD Anza Bilal Memon, MD**

No relevant financial relationships associated with the content of this activity to disclose.

Unapproved drug or product uses: Rituximab off-label use in MS treatment

**Dr. Ashlyn Mitchell, PsyD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Kristen N Myers, PharmD, BCPS**

No relevant financial relationships associated with the content of this activity to disclose.

Unapproved drug or product uses: Amoxicillin 250 mg one-time dose for the purpose of amoxicillin oral challenge per protocol approved by local Pharmacy and Therapeutics Committee.

**Loriann O'Brien, MSN, RN, CRRN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Raymond Onders, MD, FACS, FASIA**

- Synapse Biomedical: Intellectual property rights with university, Chief Medical Officer, Board Member

Unapproved drug or product uses: Use of diaphragm pacing to help injured phrenic nerves

**Dr Huned S Patwa, M.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Joseph Peters, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. Malvina Pietrzykowski, M.S.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. Annabella Prince, MSN, RN, CWCN, ET**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Korren Rapissi, RRT BA**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Christa Reckner, RN, CRRN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Malcolm Reed, OTR/L**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mrs Malin Regardt, O.T.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Beatriz Restrepo, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Susan Robinson-Whelen, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Cynthia Rolston, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mr. Grant Runnels, B.S.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Abigail Louise Ruppel, PT, DPT, NCS**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Sunil Sabharwal, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Shantanu A Satpute, M.S, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Arthur Sefiani, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Roxanne Segina, M.S. CCC-SLP**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Alessandro Serra, M.D., Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

Unapproved drug or product uses: Gabapentin, Memantine, Baclofen, 4-Aminopyridine can be used outside their FDA label to treat nystagmus and other ocular oscillations

**Dr Suma Shah, MD**

- Novartis: Consultant
- TGTherapeutics: Consultant

No discussion of unapproved drug or product uses.

**Dr. Afsaneh Shirani, MD, MSCI**

- TG Therapeutics: I have received an honorarium for serving on the TG Therapeutics advisory board
- Unapproved drug or product uses: One of the real-world cases I'll present during this meeting involves a patient who was prescribed teriflunomide off-label for primary progressive multiple sclerosis.

**Bridget Smith, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Luke Soelch, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mr. Kevin Raines Sojourner, RN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Rebecca Spain, MD, MSPH**

No relevant financial relationships associated with the content of this activity to disclose.

Unapproved drug or product uses: Alpha lipoic acid, Clemastine

**Dr. Staci Stark, RN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. Rena M Steiger-Chadwick, MPH**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Olaf Stuve, MD, Ph.D.**

- EMD Serono: Advisory board, Grant support
- Merck KGaA, Darmstadt, Germany: A 2021 recipient of a Grant for Multiple Sclerosis Innovation (GMSI), Merck KGaA, Darmstadt, Germany is funded by a Merit Review grant (federal award document number (FAIN) BX005664-01 from the United States (U.S.) Department of Veterans Affairs, Biomedical Laboratory Research and Development, is funded by RFA-2203-39314 (PI) and RFA-2203-39305 (co-PI) grants from the National Multiple Sclerosis Society (NMSS).
- Novartis: Served on data monitoring committees without monetary compensation, advisory board
- Octave Bioscience: Advisory board

No discussion of unapproved drug or product uses.

**Maria Nicole Switzer, RDN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Samuel Talisman, OTD, OTR/L**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Heather Beth Taylor, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Meghan Taylor, MAEd, MS, RDN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Ahmad Toubasi, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Michelle Brand Trbovich, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. Deanna Tuttle, M.S.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Brittany Vazquez, Psy.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Mitchell Wallin, MD, MPH**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mrs. Amber Lea Ward, MS, OTR/L, BCPR, ATP/SMS, FAOTA**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Beth Whittington, M.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Catherine S Wilson, PsyD., ABPP**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms Vanessa Veronica Wilson, BSc**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Brooks C Wingo, PhD, FACRM**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Marissa Wirth, MPH**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ka-Ho Wong, MBA**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Lindsey Wooliscroft, M.D., M.Sc., M.C.R.**

No relevant financial relationships associated with the content of this activity to disclose.

Unapproved drug or product uses: I will discuss research regarding transmagnetic stimulation for MS progression

**Dr. Lynn Worobey, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. James P. Wymer, MD**

Mitsubishi Pharma: Grant for research study paid to institution

No discussion of unapproved drug or product uses.

**Mark Thompson, MPH**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr Sivashankar Sivakanthan, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. Alicia Sloan, MPH, MSW, LICSW**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Kimberley R Monden, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Jeri Muse, Ph.D., D.A. A. P.M.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Kenneth Lee, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.



**Mr. Jacob D Herzog, RN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Colleen Counsell**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**April Marie Conway, RN, ANP-BC**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. Tommy Yu, M.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Dr. James Orengo, MD, Ph.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ms. Wendy R. Miller, BSN, RN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Lisa A McPeak, M.D.**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Bill Lawson**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Ryan Madjos, RN**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Kenneth Lee, MD**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Maureen Jennings, DPT**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.

**Mr. James Gardner, OTR/L, ATP**

No relevant financial relationships associated with the content of this activity to disclose.

No discussion of unapproved drug or product uses.